Corporate Banner
Satellite Banner
Genotyping & Gene Expression
Scientific Community
Become a Member | Sign in
Home>News>This Article

Enzo Biochem Launches Test for Measuring Risk of Colorectal Cancer

Published: Thursday, April 12, 2012
Last Updated: Thursday, April 12, 2012
Bookmark and Share
Company developing pipeline of new platforms and assays for molecular diagnostic use.

Enzo Biochem Inc. announced the launch of the ColonSentry™ test for assessing a patient’s risk of having colorectal cancer, the first in a pipeline of new molecular diagnostic products the Company plans for the medical community.
“As a pioneer in the use of genomic and genetic information as a catalyst for diagnostic products for delivering better healthcare, the availability of ColonSentry™, which only recently received New York State Department of Health approval, marks another important chapter in the transformation of our Company,” said Barry Weiner, Enzo President.  
“We also have, pending for New York State approval, our first assay based test on our new proprietary low cost and highly sensitive AmpiProbe™ nucleic acid amplification and detection technology platform.  Our AmpiProbe™ HCV RNA Quantification assay has been tested over hundreds of clinical samples and found to be reliable, accurate and precise. In addition, our assay was found, as compared to similar diagnostics products, to achieve enhanced sensitivity that can allow for a more convenient and efficient workflow which may utilize significantly less starting material and consumables.  This product is the first of several assays now under development based on the AmpiProbe™ next generation molecular diagnostics platform that are expected to be marketed both nationally and internationally.  
“These developments underscore the opportunities available to our Company through the combination of a world class clinical lab and ground breaking life science capability.  Today’s announcement of the effective roll out of ColonSentry™ is a significant achievement pointing towards a highly promising era for Enzo.”
ColonSentry™ is a first of its kind blood-based risk stratification test for colorectal cancer.  It utilizes RNA to measure the level of expression of seven specific genes. ColonSentry™ requires only a small sample of blood that can be easily collected during a routine physical exam. It is being made available as a tool to help assess a patients’ risk for colorectal cancer, and thus drive greater compliance for use of colonoscopies, which has been very low, and contribute to earlier detection of colorectal cancer.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Genetic Basis of Fatal Flu Side Effect Discovered
A group of people with fatal H1N1 flu died after their viral infections triggered a deadly hyperinflammatory disorder in susceptible individuals with gene mutations linked to the overactive immune response, according to a recent study.
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Mathematical Model Forecasts the Path of Breast Cancer
Chances of survival depend on which organs breast cancer tumors colonize first.
Ancient Viral Molecules Essential for Human Development
Genetic material from ancient viral infections is critical to human development, according to researchers at the Stanford University School of Medicine.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Personalized Drug Screening for Multiple Myeloma Patients
A personalized method for testing the effectiveness of drugs that treat multiple myeloma may predict quickly and more accurately the best treatments for individual patients with the bone marrow cancer.
Metabolic Profiles Distinguish Early Stage Ovarian Cancer with Unprecedented Accuracy
Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.
New Way to Force Stem Cells to Become Bone Cells
Potential therapies based on this discovery could help people heal bone injuries or set hardware, such as replacement knees and hips.
Promise of Newborn Stem Cells to Revolutionize Clinical Practice
In this article Shweta Sharma, PhD, discusses the potential of an Umbilical Cord Blood bank as an untapped source of samples for research and clinical trials.
New Anti-Malarial Drug Screening Model
University of South Florida researchers demonstrate novel chemogenomic profiling to identify drug targets for the most lethal strain of malaria.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos